Catalyst Dossier · compiled by CeliA 🧫
BRISTOL MYERS SQUIBB CO (CELG-RI)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-09-15 (est.)Phase 2 · Corticosteroidimp 7/10
- 2026-09-30 (est.)Phase 2 · BMS-986449imp 7/10
- 2026-10-06 (est.)Phase 3 · BMS-986278imp 9/10
- 2026-10-12 (est.)Phase 2 · CC-92480imp 7/10
- 2026-10-15 (est.)Phase 2 · Relatlimabimp 7/10
- 2026-10-31 (est.)Phase 3 · Apixabanimp 9/10
- 2026-11-18 (est.)Phase 3 · Deucravacitinibimp 9/10
- 2026-12-01 (est.)Phase 2 · Relatlimabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BMS-986249 | Phase 2 | Advanced Cancer |
| BMS-754807 | Phase 2 | Breast Cancer |
| Aurexis® | Phase 2 | Staphylococcus Aureus Bacteremia |
| Atazanavir/Ritonavir | Phase 3 | HIV |
| Vitamin K Antagonist (VKA) | Phase 2 | Thrombosis |
| CXL-1020 | Phase 2 | Heart Failure |
| Stavudine | Phase 3 | HIV Infections |
| Oral Taxane | Phase 2 | Non-small Cell Lung Cancer |
| BMS-986253 | Phase 2 | Cancer |
| Temozolomide 50mg/m2/day | Phase 2 | Adenocarcinoma - GEJ |
| BMS-986322 | Phase 2 | Psoriasis |
| Mavacamten | Phase 3 | Cardiomyopathy, Hypertrophic |
| BMS-986490 | Phase 2 | Advanced Solid Tumors |
| Abatacept | Phase 3 | Rheumatoid Arthritis |
| MYK-491 | Phase 2 | Heart Failure With Reduced Ejection Fraction |
| Entecavir | Phase 3 | Hepatitis B, Chronic |
| Elotuzumab | Phase 3 | Multiple Myeloma |
| Mezigdomide | Phase 3 | Relapsed or Refractory Multiple Myeloma |
| PSI-7977 | Phase 2 | Chronic Hepatitis C |
| Epoetin Alfa | Phase 3 | Myelodysplastic Syndromes |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$0.11–$0.11
vs 50-day MA
—
vs 200-day MA
—
Realized vol
—
Max drawdown
0.0%
Daily closes through 2026-09-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CELG-RI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.